Netarsudil Dimesylate

N/A

Report date: 2025/03/12 15:25:51
NMEFirst In Class

Base Information

Drug NameNetarsudil Dimesylate
Drug Alias Namenetarsudilum奈舒地尔奈他地尔netarsudilnetarsudil mesylate +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated kinases inhibitorsNorepinephrine transporter inhibitors
TargetsRho-associated kinasesNorepinephrine transporter
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension +[5] 
Global Approved IndicationsGlaucoma, Open-AngleOcular Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/12/18
Country/TerritoryUnited StatesEUJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAerie Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanten OyAlconAerie Pharmaceuticals Inc +[4] 
Inactive CompaniesUniversity Of The Incarnate WordPrice Vision Group
Active IndicationsGlaucoma, Open-AngleOcular HypertensionCorneal Edema
Inactive IndicationsGlaucomaFuchs' Endothelial Dystrophy

Other Information

ATC CodeS01EX05
Related LinksWikipediaDrugBankKEGG